EXTON, Pa.--(BUSINESS WIRE)--Absorption Systems LP today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the U.S. Food and Drug Administration (FDA) to continue development of the company’s CellPort Technologies™ testing platform. This unique assay platform enables more specific prediction of potential drug-drug interactions mediated by human drug transport proteins. CellPort Technologies will become a key component of what is referred to as “Translational Medicine,” the process of translating the results from in vitro assays in model systems into human outcomes in the clinic.
